Valdecoxib is a nonsteroidal anti-inflammatory drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995. Valdecoxib exhibits potent COX-2 selectivity with minimal COX-1 inhibition, providing analgesic and anti-inflammatory effects through suppression of prostaglandin synthesis. The active pharmaceutical ingredient is formulated for oral delivery; it has reasonable oral bioavailability and is subject to hepatic metabolism with formation of oxidative and conjugated metabolites. Typical preformulation and formulation considerations include low aqueous solubility, stability to normal storage conditions, and susceptibility to oxidative and photolytic degradation, which guide choice of excipients and packaging. Standard analytical controls use reversed-phase HPLC for assay and related substances, and methods for residual solvents, heavy metals, and microbial limits are applied during manufacture.
Parent: Valdecoxib
Parent: Valdecoxib
Typical quality specifications for valdecoxib active substance and finished forms address assay, related substances, and controlled impurities using validated HPLC methods and compendial tests. A representative specification framework used in manufacturing includes assay 98.0 to 102.0 percent (by HPLC), individual specified related compounds not more than 0.1 to 0.2 percent, total impurities not more than 0.5 percent, residual solvents within ICH Q3C limits, water content generally under 0.5 percent, and heavy metals below 20 parts per million, with stricter limits applied to any potential genotoxic impurities. Common related compounds and degradation products encountered in process and stability studies include N-oxide and N-dealkylated metabolites, sulfoxide and sulfone oxidation products, desmethyl and other O- or N-dealkylation products, and positional isomers; each is monitored and controlled by identification, quantification, and appropriate acceptance criteria as part of the drug substance and drug product specifications.
Valdecoxib was developed and used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and dysmenorrhea; its therapeutic effect derives from selective inhibition of the cyclooxygenase-2 enzyme, reducing prostaglandin-mediated pain and inflammation.
Valdecoxib was withdrawn from the global market primarily because postmarketing safety data showed an increased risk of serious cardiovascular events and reports of severe dermatological reactions; manufacturers and regulators removed it to mitigate those identified risks.
Valdecoxib was previously approved by the US Food and Drug Administration for specific indications, but its approval was withdrawn and it is not currently an FDA-approved marketed product.
